Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR6 | P43657 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583616 | 0.80 | ALDH1A1 (0.33) | — | |
| SCHEMBL20319816 | 0.80 | LPAR6 (0.35) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL6582460 | 0.79 | LPAR6 (0.31) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL3815702 | 0.79 | TSHR (0.38) | — | |
| SCHEMBL5724019 | 0.78 | CTSK (0.33) | — | |
| SCHEMBL1469728 | 0.76 | ACACB (0.38) | LPAR6LPAR1LPAR4LPAR5LPAR2 | |
| SCHEMBL6580803 | 0.75 | TSHR (0.37) | — | |
| SCHEMBL6894951 | 0.75 | CTSK (0.38) | PRKCA | |
| SCHEMBL304539 | 0.74 | — | — | |
| SCHEMBL12987306 | 0.74 | AR (0.32) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1437352-A1 | BENZIMIDAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | SI, MLNR, FABP2 | LPAR6 4858/4885LPAR1 4853/4885LPAR4 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.